ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 84 citations in OpenAlex.
- MicroRNA-mediated regulation of ferroptosis via GPX4: mechanisms and therapeutic opportunities.Molecular biology reports · 2026Review
- Colorectal cancer cells-derived exosomal miR-188-3p promotes liver metastasis by creating a pre-metastatic niche via activation of hepatic stellate cells.Journal of translational medicine · 2025Article
- Profiling of miRNAs Contained in Circulating Extracellular Vesicles and Associated with Sepsis Development in Burn Patients: A Proof-of-Concept Study.International journal of molecular sciences · 2025Article
- LINC00673 binds with leptin to regulate osteogenic function in periodontal ligament stem cells.Journal of orthopaedic surgery and research · 2025Article
- Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer.Open medicine (Warsaw, Poland) · 2025Article
- A novel serum mFrontiers in genetics · 2024Article
- Circular RNA circBLNK promotes osteosarcoma progression and inhibits ferroptosis in osteosarcoma cells by sponging miR‑188‑3p and regulating GPX4 expression.Oncology reports · 2023Article
- Article
- Antitumor activity of miR-188-3p in gastric cancer is achieved by targeting CBL expression and inactivating the AKT/mTOR signaling.World journal of gastrointestinal oncology · 2023Article
- Circular RNA circ0001955 promotes cervical cancer tumorigenesis and metastasis via the miR-188-3p/NCAPG2 axis.Journal of translational medicine · 2023Article
- Review
- PaintOmics 4: new tools for the integrative analysis of multi-omics datasets supported by multiple pathway databases.Nucleic acids research · 2022Article
- Epigenetic Regulation in Exposome-Induced Tumorigenesis: Emerging Roles of ncRNAs.Biomolecules · 2022Review
- RNA mOncology letters · 2021Article
- Article
- miR-188-5p promotes oxaliplatin resistance by targeting RASA1 in colon cancer cells.Oncology letters · 2021Article
- lncRNA APOC1P1-3 promoting anoikis-resistance of breast cancer cells.Cancer cell international · 2021Article
- Emerging Role of Non-Coding RNAs in Regulation of T-Lymphocyte Function.Frontiers in immunology · 2021Review
- Increased miR-188-3p in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome.Computational and mathematical methods in medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
Martin PichlerDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. gcalin@mdanderson.org martin.pichler@medunigraz.at.
Verena StiegelbauerDivision of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.
Petra Vychytilova-FaltejskovaMolecular Oncology II - Solid Cancers, Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Cristina IvanDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hui LingDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Elke WinterInstitute of Pathology, Medical University of Graz (MUG), Graz, Austria.
Xinna ZhangThe Center for RNA Interference and Non-coding RNAs, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Matthew GoblirschDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Annika Wulf-GoldenbergExperimental Pharmacology & Oncology GmbH, EPO, Berlin-Buch, Germany.
Masahisa OhtsukaDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Johannes HaybaeckInstitute of Pathology, Medical University of Graz (MUG), Graz, Austria.
Marek SvobodaDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Yoshinaga OkugawaCenter for Gastrointestinal Research and Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.
Armin GergerDivision of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.
Gerald HoeflerInstitute of Pathology, Medical University of Graz (MUG), Graz, Austria.
Ajay GoelCenter for Gastrointestinal Research and Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.
Ondrej SlabyMolecular Oncology II - Solid Cancers, Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
George Adrian CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. gcalin@mdanderson.org martin.pichler@medunigraz.at.
The University of Texas MD Anderson Cancer Center · USMedical University of Graz · ATBaylor University Medical Center · USCentral European Institute of Technology · CZEuropean Patent Organisation · DEMasaryk Memorial Cancer Institute · CZ
Funding
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7MTargeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2002 to 2012
$26.1MTRAINING OF ACADEMIC SURGICAL ONCOLOGISTST32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Ashley M Holder, Jennifer A. Wargo · 1988 to 2026
$13.2MThe Biology and Diagnosis of HNPCCR01CA072851 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GOEL, AJAY · 1996 to 2019
$6.6MProtein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9MMETHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCERR01CA181572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2014 to 2018
$1.6MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH2TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2013 to 2014
$1.1MNCATS NIH HHS UH2 TR000943NCI NIH HHS P50 CA097007NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA072851NCI NIH HHS R01 CA181572NCI NIH HHS R01 CA182905NCI NIH HHS T32 CA009599
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsBiomarkers, TumorCarcinogenesisColorectal NeoplasmsFemaleGenome, HumanHCT116 CellsHigh-Throughput Nucleotide SequencingHumansKinesinsMaleMiceMicroRNAsMyosinsPrognosisTranscriptomeAFDN protein, humanBiomarkers, TumorKinesinsMicroRNAsMIRN188 microRNA, humanMyosins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.